Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study.
Chwojnicki K, Iwaszkiewicz-Grześ D, Jankowska A, Zieliński M, Łowiec P, Gliwiński M, Grzywińska M, Kowalczyk K, Konarzewska A, Glasner P, Sakowska J, Kulczycka J, Jaźwińska-Curyłło A, Kubach M, Karaszewski B, Nyka W, Szurowska E, Trzonkowski P.
Chwojnicki K, et al.
BioDrugs. 2021 Jan;35(1):47-60. doi: 10.1007/s40259-020-00462-7. Epub 2021 Jan 5.
BioDrugs. 2021.
PMID: 33400237
Clinical Trial.
RESULTS: No severe adverse events were observed. Self-assessed quality of life (EuroQol-5 Dimensions [EQ-5D] form) did not change and did not differ significantly between the groups. ...Because of the low number of patients recruited, the statistical results may be underpo …
RESULTS: No severe adverse events were observed. Self-assessed quality of life (EuroQol-5 Dimensions [EQ-5D] form) did not change and …